Neurocentrx Reports Positive Top-line Results from Phase 1 Clinical Study of its Lead Oral Ketamine Capsule Programme
EDINBURGH, Scotland--(BUSINESS WIRE)--Neurocentrx (the Company), a biopharmaceutical company specialising in oral ketamine for the treatment of mood disorders and other neurological indications, today provides a positive update on the clinical development of its lead programme, Keticap®. Neurocentrx has operations in the UK and is embarking on a growth phase and seeking corporate partners and investors.